Efforts to reform the structure of the German pharmaceutical industry organization, the BPI, have failed after some two years of debate. A recommendation to set up a number of specialist bodies representing various sectors of the industry under one roof failed to achieve the required two-thirds majority at an extraordinary general meeting in Cologne.
Only 49 of the 91 delegates voted for the one-roof solution. Those rejecting the proposal said that it would leave the general BPI organization with too little political weight in comparison with the other constitutional bodies.
The individual bodies would set up their own public relations organizations and the BPI, as an umbrella organization, would be left to represent the industry only on themes on which there was consensus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze